Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
Open original source
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
Open original source